WednesdayFeb 25, 2026 10:00 am

Engineered Nanoparticles Hold Promise in Delivering Precision Cancer Treatments

McGill University researchers have built tiny particle carriers that can shuttle cancer drugs straight to diseased lymph nodes without touching healthy tissue, reducing toxic side effects in mice compared to conventional whole-body treatment. The method tackles cancer that has spread into the lymphatic system, a particularly tough stage that typically forces surgeons to remove affected nodes despite their essential role in coordinating immune responses throughout the body.  Standard immunotherapy floods the bloodstream through IV infusion, activating immune responses indiscriminately across organs and tissues in ways that can grow dangerous enough to require dose cuts that weaken treatment. McGill Biomedical Engineering Assistant Professor Guojun Chen says certain immunotherapies trigger reactions so…

Continue Reading

WednesdayFeb 25, 2026 9:45 am

Rail Vision Ltd. (NASDAQ: RVSN) Subsidiary Advances Quantum AI Strategy with New Neural Decoder Breakthrough

Quantum Transportation’s system represents a patented prototype machine-learning-driven decoder aimed at addressing the complex challenges of universal quantum error correction. The company describes the technology as code agnostic, meaning it can generalize across multiple quantum error-correction frameworks rather than being limited to a single code family. Company leadership framed the unveiling as part of a longer-term technological exploration. Advancements in artificial intelligence and quantum computing continue to reshape how researchers approach complex computational challenges, particularly in areas such as error correction and large-scale data processing. A recent development in this space highlights the growing intersection between machine learning architectures and…

Continue Reading

MondayFeb 23, 2026 10:30 am

Datavault AI Inc. (NASDAQ: DVLT) Expanded Digital Engagement Through Dream Bowl Meme Token, Major Event Partnership

Wellgistics sponsored Dream Bowl 2026 and participated in the Datavault AI shareholder distribution plan for the Dream Bowl 2026 meme coin.  The first-ever Dream Bowl 2026 meme coin was not a financial instrument or a currency but was a digital collectible with utility tied to the event experience.  Datavault AI’s broader mission centers on advancing AI-driven data experiences, valuation and monetization of digital assets within the Web3 environment. Datavault AI (NASDAQ: DVLT) gained attention for its role in an innovative digital collectible initiative tied to one of the most anticipated sporting events of early 2026. Through a sponsorship arrangement with Wellgistics…

Continue Reading

MondayFeb 23, 2026 9:00 am

Canadian Defense Strategy Categorizes Quantum Computing as a High-Value Sector

Ottawa's latest defense industrial roadmap treats quantum computing as a strategic priority requiring government protection and accelerated development. Quantum sits alongside artificial intelligence, critical minerals, munitions, and space technologies as sectors vital for military capability and economic security. Rather than issuing a dedicated quantum plan, policymakers embedded it within a broader mobilization strategy linking research institutions, commercial developers, and defense procurement systems. Federal planners are now building mechanisms to connect university laboratories with defense contractors and military buyers. The goal is to compress the timeline from scientific breakthrough to battlefield deployment. This approach marks a policy shift from treating quantum…

Continue Reading

MondayFeb 23, 2026 9:00 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Expands into Proton Therapy Through Liora Technologies, Advancing the LiGHT System for Next-Generation Cancer Care

LIXTE has acquired Liora Technologies Europe Ltd., securing its proprietary LiGHT system for advanced proton therapy treatment Liora works at the forefront of electronically controlled proton beam innovation, with its platform installed at the UK’s STFC Daresbury Laboratory These updates highlight LIXTE’s overarching mission to blend breakthrough drug development with transformative radiotherapy innovations in the global cancer fight Cancer is still one of the most widespread life-threatening diseases globally, with nearly all families affected either directly or as caregivers. Innovations in the medical ecosystem continue to gain momentum with the emergence of new immunotherapies, targeted drugs, and advanced radiation treatments.…

Continue Reading

FridayFeb 20, 2026 10:30 am

GridAI Corp. (NASDAQ: GRDX) Committed to Optimization of Energy Management to Meet Hyperscale AI Data Center Demands

With a focus on energy orchestration software rather than grid hardware or power generation, GridAI addresses the immediate need to coordinate and control energy throughout hyperscale AI campuses. With rising AI-driven electricity demand rapidly exposing the limits of traditional grid planning cycles, GridAI’s model centers on real-time coordination of existing assets and allows hyperscalers to optimize the design of new infrastructure buildout. The company’s platform operates across the entire data center campus, managing grid power, on-site generation, battery storage, and market participation, to position energy control as a financial and operational lever for large power users. For much of the…

Continue Reading

WednesdayFeb 18, 2026 10:00 am

Pressure from Brain Tumors Triggers Self-Destruct Mechanism in Neurons, Study Finds

Brain tumors may damage surrounding tissue in a more insidious way than previously understood. New research from the University of Notre Dame shows that chronic pressure from an expanding tumor does not simply crush nearby neurons. It activates an internal self-destruction program that pushes those cells toward death.  Neurons form the backbone of thought, movement and sensation. When they die, the brain cannot easily replace them. That loss often leads to cognitive decline, motor impairment and sensory deficits seen in patients with aggressive brain cancers and traumatic injuries.  An interdisciplinary team at the University of Notre Dame set out to examine how mechanical compression alone affects healthy brain cells. Meenal Datta, a professor of aerospace and mechanical engineering…

Continue Reading

WednesdayFeb 18, 2026 9:45 am

When Cancer Care Hits a Hardware Wall, One Microcap Is Building Around It

In oncology, the biggest constraints are not always science. They are often the logistics, the cost of specialized infrastructure, and the difficulty of scaling advanced treatment capacity fast enough to meet demand. A Two-Track Strategy: Sensitizing Tumors, Modernizing Delivery LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) is pursuing a model that tries to improve cancer outcomes from two directions at once. On the therapeutic side, the company’s lead asset is LB-100, a clinical-stage compound designed to inhibit protein phosphatase 2A (“PP2A”), a biological target involved in cellular stress response and DNA repair pathways. LIXTE’s stated strategy is not to replace standard…

Continue Reading

TuesdayFeb 17, 2026 10:00 am

Existing Cancer Drug Shows Potential in Reactivating Immunotherapy

An already approved cancer drug called Carfilzomib may help restore the effectiveness of CAR-T cell therapy in advanced multiple myeloma cases. Technical University of Munich researchers have discovered a molecular mechanism that causes cancer cells to evade treatment and have shown that blocking it can make immunotherapy work again in some patients.  CAR-T cell therapy involves removing a patient's T cells, genetically altering them in the laboratory, and reintroducing them so they can recognize and attack cancer cells. For multiple myeloma, these engineered cells target a molecule known as BCMA, which appears on diseased plasma cells. The approach can extend survival, sometimes by years,…

Continue Reading

FridayFeb 13, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Focused on Dual Narratives of Scientific Progress, Social Engagement

LIXTE recently announced advances in its approach to cancer therapy through its proprietary compound LB-100 Alongside clinical development news, LIXTE is sponsoring the Good Health: Mind, Body & Soul Summit These two announcements paint a picture of a company advancing on multiple fronts LIXTE Biotechnology Holdings (NASDAQ: LIXT) is entering 2026 with momentum on both scientific and community fronts, announcing progress in its lead oncology program while also sponsoring a major health and wellness summit focused on addressing disparities in care. The company’s announcements highlight advances surrounding LB-100, its first-in-class cancer therapy candidate designed to enhance the effectiveness of existing treatments and underscore its…

Continue Reading

Contact us: (512) 354-7000